EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intensive care unit outcomes in patients with hematological malignancy

Jarrod Leigh Rawson, Fionnuala Mary Fagan, Georgin Claire Burrough, Helen Michelle Tang, Moire Alys Cuncannon, Katrina Louise Ellem, Anoop Kumar Enjeti

Blood Science · 2020-01 · 2 (1) · 33-37

DOI: 10.1097/bs9.0000000000000038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Science, 2020-01. Verfasst von Jarrod Leigh Rawson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Calvary Mater Newcastle, NSW. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematological malignancies are usually life-limiting conditions. Limitations of care need to be decided early, based on acceptability to the patient, family, physician, and community. Inappropriate intensive care unit (ICU) admission is likely to result in significant physical, psychological, and economic burden. There is little published on the impact of non-acute preadmission disease factors on ICU outcomes in hematological malignancies.

Aim

To identify baseline performance and disease-associated factors before admission to ICU in patients with hematological malignancy that contribute to subsequent ICU mortality.

Methods

A retrospective analysis of electronic medical records, laboratory results, and Intensive Care data for all patients ( n = 184) with hematological malignancy admitted to the Calvary Mater Hospital ICU between January 1, 2013 and June 30, 2017 was undertaken. Baseline age, gender, condition, Eastern Cooperative Oncology, and Charlson Comorbidity scores were compared to ICU outcome and overall survival. Disease-specific prognostic risk scores were compared to ICU outcome.

Results

Overall, 73.9% survived the ICU admission, with 31.6% surviving at 12 months. Superior ejection fractions (>55%) and prognosis >12 months (based on disease-specific risk scores) were significantly associated with overall survival ( P = 0.024 and P = 0.001). Induction and posttransplantation therapy were predictive of poor ICU survival outcome ( P < 0.0001 and P = 0.041). APACHE scores were significant predictors of ICU mortality ( P = 0.002 for APACHE II and P < 0.0001 for APACHE III).

Conclusion

Survival outcomes for patients with hematological malignancy admitted to the ICU correlate with functional and comorbidity status. Disease-specific prognostic scores can assist in recognizing patients likely to benefit from ICU admission.

Schlagwörter

Stichwörter der Autor:innen

ComorbidityHematologic malignancyIntensive carePrognosis

Autor:innen und Institutionen

  • Hematology Unit, Calvary Mater Newcastle, NSW.
  • NSW Health Pathology North-Hunter.
  • Intensive Care Unit, Calvary Mater Newcastle, NSW.
  • University of Newcastle, Callaghan, NSW.
  • Hunter Medical Research Institute, New Lambton, NSW.
  • Hunter Cancer Research Alliance, NSW.

Zitieren

APA

Rawson, J. L., Fagan, F. M., Burrough, G. C., Tang, H. M., Cuncannon, M. A., Ellem, K. L., & Enjeti, A. K. (2020). Intensive care unit outcomes in patients with hematological malignancy. Blood Science, 2(1), 33-37. https://doi.org/10.1097/bs9.0000000000000038

Vancouver

Rawson JL, Fagan FM, Burrough GC, Tang HM, Cuncannon MA, Ellem KL, et al. Intensive care unit outcomes in patients with hematological malignancy. Blood Science. 2020;2(1):33-37. doi:10.1097/bs9.0000000000000038

BibTeX
@article{Rawson2020,
  author = {Rawson, Jarrod Leigh and Fagan, Fionnuala Mary and Burrough, Georgin Claire and Tang, Helen Michelle and Cuncannon, Moire Alys and Ellem, Katrina Louise and Enjeti, Anoop Kumar},
  title = {Intensive care unit outcomes in patients with hematological malignancy},
  journal = {Blood Science},
  year = {2020},
  volume = {2},
  number = {1},
  pages = {33--37},
  doi = {10.1097/bs9.0000000000000038}
}
Kostenlos starten →